{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:02:18Z","timestamp":1791608538569,"version":"4.3.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-025-07769-7","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:29:30Z","timestamp":1741249770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Potent and broadly neutralizing antibodies against sarbecoviruses elicited by single ancestral SARS-CoV-2 infection"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-9479","authenticated-orcid":false,"given":"Lei","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanchen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2933-0003","authenticated-orcid":false,"given":"Xiaomin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1931-8687","authenticated-orcid":false,"given":"Wentai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-9104","authenticated-orcid":false,"given":"Xiaoyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxue","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6335-5648","authenticated-orcid":false,"given":"Hongjie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6546-2095","authenticated-orcid":false,"given":"Yongjun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-9837","authenticated-orcid":false,"given":"Hin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8741-0202","authenticated-orcid":false,"given":"Lei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2454-7652","authenticated-orcid":false,"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"7769_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41392-024-01846-9","volume":"9","author":"H. H Liu","year":"2024","unstructured":"Liu, H. H. et al. Safety, immunogenicity and protective effect of sequential vaccination with inactivated and recombinant protein COVID-19 vaccine in the elderly: a prospective longitudinal study. Signal Transduct. Target. Ther. 9, 129 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7769_CR2","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","volume":"19","author":"H Yang","year":"2021","unstructured":"Yang, H. & Rao, Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 19, 685\u2013700 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"7769_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","volume":"7","author":"W Yan","year":"2022","unstructured":"Yan, W., Zheng, Y., Zeng, X., He, B. & Cheng, W. Structural biology of SARS-CoV-2: open the door for novel therapies. Signal Transduct. Target. Ther. 7, 26 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7769_CR4","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41577-022-00784-3","volume":"23","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat. Rev. Immunol. 23, 189\u2013199 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"7769_CR5","doi-asserted-by":"publisher","first-page":"112014","DOI":"10.1016\/j.celrep.2023.112014","volume":"42","author":"H. M Callaway","year":"2023","unstructured":"Callaway, H. M. et al. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. Cell Rep. 42, 112014 (2023).","journal-title":"Cell Rep."},{"key":"7769_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","volume":"186","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 186, 279\u2013286 e278 (2023).","journal-title":"Cell"},{"key":"7769_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-022-04594-4","volume":"604","author":"S Iketani","year":"2022","unstructured":"Iketani, S. et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 604, 553\u2013556 (2022).","journal-title":"Nature"},{"key":"7769_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00751-24","volume":"15","author":"P Li","year":"2024","unstructured":"Li, P. et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion. mBio 15, e0075124 (2024).","journal-title":"mBio"},{"key":"7769_CR9","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"7769_CR10","unstructured":"FDA. Data from \u201cEmergency Use Authorizations for Drugs and Non-Vaccine Biological Products.\u201d https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/emergency-use-authorizations-drugs-and-non-vaccine-biological-products."},{"key":"7769_CR11","doi-asserted-by":"crossref","unstructured":"COVID-19 update: An EUA for pemivibart (Pemgarda) for pre-exposure prophylaxis. Med. Lett. Drugs Ther. 66, 79\u201380 (2024).","DOI":"10.58347\/tml.2024.1702e"},{"key":"7769_CR12","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"7769_CR13","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41586-020-2548-6","volume":"584","author":"S. J Zost","year":"2020","unstructured":"Zost, S. J. et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443\u2013449 (2020).","journal-title":"Nature"},{"key":"7769_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41586-020-2380-z","volume":"584","author":"B Ju","year":"2020","unstructured":"Ju, B. et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature 584, 115\u2013119 (2020).","journal-title":"Nature"},{"key":"7769_CR15","first-page":"521","volume":"614","author":"Y Cao","year":"2023","unstructured":"Cao, Y. et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 614, 521\u2013529 (2023).","journal-title":"Nature"},{"key":"7769_CR16","doi-asserted-by":"publisher","first-page":"125997","DOI":"10.1016\/j.ijbiomac.2023.125997","volume":"249","author":"L Wang","year":"2023","unstructured":"Wang, L., Wang, Y. & Zhou, H. Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants. Int. J. Biol. Macromol. 249, 125997 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"7769_CR17","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf, K. et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 39, 110812 (2022).","journal-title":"Cell Rep."},{"key":"7769_CR18","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"7769_CR19","doi-asserted-by":"publisher","first-page":"101445","DOI":"10.1016\/j.xcrm.2024.101445","volume":"5","author":"Z Liu","year":"2024","unstructured":"Liu, Z. et al. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD. Cell Rep. Med. 5, 101445 (2024).","journal-title":"Cell Rep. Med."},{"key":"7769_CR20","doi-asserted-by":"publisher","first-page":"111845","DOI":"10.1016\/j.celrep.2022.111845","volume":"41","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep. 41, 111845 (2022).","journal-title":"Cell Rep."},{"key":"7769_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/22221751.2021.2024455","volume":"11","author":"S Xu","year":"2022","unstructured":"Xu, S. et al. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerg. Microbes Infect. 11, 351\u2013367 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"7769_CR22","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41586-022-04581-9","volume":"604","author":"Q Hong","year":"2022","unstructured":"Hong, Q. et al. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546\u2013552 (2022).","journal-title":"Nature"},{"key":"7769_CR23","doi-asserted-by":"publisher","first-page":"eade0958","DOI":"10.1126\/sciimmunol.ade0958","volume":"8","author":"F Bianchini","year":"2023","unstructured":"Bianchini, F. et al. Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein. Sci. Immunol. 8, eade0958 (2023).","journal-title":"Sci. Immunol."},{"key":"7769_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1126\/science.abj3321","volume":"373","author":"D Pinto","year":"2021","unstructured":"Pinto, D. et al. Broad betacoronavirus neutralization by a stem helix-specific human antibody. Science 373, 1109\u20131116 (2021).","journal-title":"Science"},{"key":"7769_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.abq3773","volume":"377","author":"C Dacon","year":"2022","unstructured":"Dacon, C. et al. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science 377, 728\u2013735 (2022).","journal-title":"Science"},{"key":"7769_CR26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.immuni.2023.02.005","volume":"56","author":"P Zhou","year":"2023","unstructured":"Zhou, P. et al. Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. Immunity 56, 669\u2013686.e667 (2023).","journal-title":"Immunity"},{"key":"7769_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/s41421-024-00648-1","volume":"10","author":"X Zhao","year":"2024","unstructured":"Zhao, X. et al. Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination. Cell Discov. 10, 14 (2024).","journal-title":"Cell Discov."},{"key":"7769_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36295-5","volume":"14","author":"R Rouet","year":"2023","unstructured":"Rouet, R. et al. Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients. Nat. Commun. 14, 687 (2023).","journal-title":"Nat. Commun."},{"key":"7769_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41392-023-01615-0","volume":"8","author":"Q Liu","year":"2023","unstructured":"Liu, Q. et al. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge. Signal Transduct. Target. Ther. 8, 347 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"7769_CR30","doi-asserted-by":"crossref","unstructured":"Yu, L. et al. Monoclonal antibodies against zika virus NS1 protein confer protection via Fc\u03b3 receptor-dependent and -independent pathways. mBio 12, e03179-20 (2021).","DOI":"10.1128\/mBio.03179-20"},{"key":"7769_CR31","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1073\/pnas.0813392106","volume":"106","author":"Y Guan","year":"2009","unstructured":"Guan, Y. et al. Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. Proc. Natl Acad. Sci. USA 106, 3952\u20133957 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7769_CR32","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.chom.2021.04.005","volume":"29","author":"H Liu","year":"2021","unstructured":"Liu, H. et al. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe 29, 806\u2013818.e806 (2021).","journal-title":"Cell Host Microbe"},{"key":"7769_CR33","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-022-00684-0","volume":"32","author":"Y Wang","year":"2022","unstructured":"Wang, Y. et al. A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. Cell Res. 32, 862\u2013865 (2022).","journal-title":"Cell Res."},{"key":"7769_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00480-22","volume":"96","author":"W Zhan","year":"2022","unstructured":"Zhan, W. et al. Structural study of SARS-CoV-2 antibodies identifies a broad-spectrum antibody that neutralizes the omicron variant by disassembling the spike trimer. J. Virol. 96, e0048022 (2022).","journal-title":"J. Virol."},{"key":"7769_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27610-z","volume":"13","author":"L Hanke","year":"2022","unstructured":"Hanke, L. et al. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat. Commun. 13, 155 (2022).","journal-title":"Nat. Commun."},{"key":"7769_CR36","doi-asserted-by":"publisher","first-page":"100991","DOI":"10.1016\/j.drup.2023.100991","volume":"71","author":"D Focosi","year":"2023","unstructured":"Focosi, D., McConnell, S., Sullivan, D. J. & Casadevall, A. Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment. Drug Resist. Updat. 71, 100991 (2023).","journal-title":"Drug Resist. Updat."},{"key":"7769_CR37","doi-asserted-by":"crossref","unstructured":"Casadevall, A. & Focosi, D. SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern. J. Clin. Invest. 133, e168603 (2023).","DOI":"10.1172\/JCI168603"},{"key":"7769_CR38","doi-asserted-by":"crossref","unstructured":"Yu, L. et al. Delineating antibody recognition against Zika virus during natural infection. JCI Insight 2, e93042 (2017).","DOI":"10.1172\/jci.insight.93042"},{"key":"7769_CR39","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112\u2013124 (2008).","journal-title":"J. Immunol. Methods"},{"key":"7769_CR40","doi-asserted-by":"publisher","first-page":"5090","DOI":"10.1002\/jmv.28017","volume":"94","author":"X Wang","year":"2022","unstructured":"Wang, X. et al. Neutralization of distinct Omicron sublineages by longitudinal vaccination sera. J. Med. Virol. 94, 5090\u20135092 (2022).","journal-title":"J. Med. Virol."},{"key":"7769_CR41","doi-asserted-by":"crossref","unstructured":"Chu, H. et al. Targeting highly pathogenic coronavirus-induced apoptosis reduces viral pathogenesis and disease severity. Sci. Adv. 7, eabf8577 (2021).","DOI":"10.1126\/sciadv.abf8577"},{"key":"7769_CR42","first-page":"785","volume":"609","author":"H Chu","year":"2022","unstructured":"Chu, H. et al. Coronaviruses exploit a host cysteine-aspartic protease for replication. Nature 609, 785\u2013792 (2022).","journal-title":"Nature"},{"key":"7769_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104916","volume":"99","author":"B Hu","year":"2024","unstructured":"Hu, B. et al. Divergent trajectory of replication and intrinsic pathogenicity of SARS-CoV-2 Omicron post-BA.2\/5 subvariants in the upper and lower respiratory tract. EBioMedicine 99, 104916 (2024).","journal-title":"EBioMedicine"},{"key":"7769_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104753","volume":"95","author":"H Shuai","year":"2023","unstructured":"Shuai, H. et al. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5. EBioMedicine 95, 104753 (2023).","journal-title":"EBioMedicine"},{"key":"7769_CR45","doi-asserted-by":"publisher","first-page":"eadd3867","DOI":"10.1126\/sciadv.add3867","volume":"9","author":"J. F Chan","year":"2023","unstructured":"Chan, J. F. et al. Altered host protease determinants for SARS-CoV-2 Omicron. Sci. Adv. 9, eadd3867 (2023).","journal-title":"Sci. Adv."},{"key":"7769_CR46","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1126\/science.abd0826","volume":"369","author":"C. L Hsieh","year":"2020","unstructured":"Hsieh, C. L. et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 369, 1501\u20131505 (2020).","journal-title":"Science"},{"key":"7769_CR47","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"7769_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39031-1","volume":"14","author":"J He","year":"2023","unstructured":"He, J., Li, T. & Huang, S. Y. Improvement of cryo-EM maps by simultaneous local and non-local deep learning. Nat. Commun. 14, 3217 (2023).","journal-title":"Nat. Commun."},{"key":"7769_CR49","doi-asserted-by":"publisher","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse, A. et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296\u2013W303 (2018).","journal-title":"Nucleic Acids Res."},{"key":"7769_CR50","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"E. F Pettersen","year":"2004","unstructured":"Pettersen, E. F. et al. UCSF Chimera\u2013a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605\u20131612 (2004).","journal-title":"J. Comput. Chem."},{"key":"7769_CR51","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. Sect. D66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"7769_CR52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1107\/S2059798318006551","volume":"74","author":"P. V Afonine","year":"2018","unstructured":"Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. Sect. D74, 531\u2013544 (2018).","journal-title":"Acta Crystallogr. Sect. D"},{"key":"7769_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","volume":"30","author":"E. F Pettersen","year":"2021","unstructured":"Pettersen, E. F. et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 30, 70\u201382 (2021).","journal-title":"Protein Sci."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07769-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:49:57Z","timestamp":1741290597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-025-07769-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7769"],"URL":"https:\/\/doi.org\/10.1038\/s42003-025-07769-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.06.597720","asserted-by":"object"}]},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"19 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.G. is a co-founder and shareholder of Antibody BioPharm, Inc. and ChangYuan FuNeng (Shanghai) Life Technology Co., Ltd. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}